These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36499277)

  • 1. Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer.
    von Amsberg G; Zilles M; Mansour W; Gild P; Alsdorf W; Kaune M; Böckelmann L; Hauschild J; Krisp C; Rohlfing T; Saygi C; Alawi M; Zielinski A; Langebrake C; Oh-Hohenhorst SJ; Perner S; Tilki D; Schlüter H; Graefen M; Dyshlovoy SA; Bokemeyer C
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
    Rusarova N; Vitaskova D; Kalabova H; Ondruskova A; Purova D; Melichar B; Studentova H
    Future Oncol; 2022 Dec; 18(38):4183-4192. PubMed ID: 36519589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
    Ruiz de Porras V; Wang XC; Palomero L; Marin-Aguilera M; Solé-Blanch C; Indacochea A; Jimenez N; Bystrup S; Bakht M; Conteduca V; Piulats JM; Buisan O; Suarez JF; Pardo JC; Castro E; Olmos D; Beltran H; Mellado B; Martinez-Balibrea E; Font A; Aytes A
    Eur Urol; 2021 Jun; 79(6):722-733. PubMed ID: 33153817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
    Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
    Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
    Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
    Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
    Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
    Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
    Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response to paclitaxel, ifosfamide, and cisplatin therapy in a case of ovarian ependymoma.
    Hino M; Kobayashi Y; Wada M; Hattori Y; Kurahasi T; Nakagawa H
    J Obstet Gynaecol Res; 2016 Nov; 42(11):1613-1617. PubMed ID: 27785897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
    Takayama T; Sugiyama T; Furuse H; Yajima T; Suzuki T; Kai F; Nagata M; Otsuka A; Ishii Y; Ozono S
    Nihon Hinyokika Gakkai Zasshi; 2013 Nov; 104(6):681-7. PubMed ID: 24564074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.
    Kawai K; Miyazaki J; Tsukamoto S; Hinotsu S; Hattori K; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2003 Mar; 33(3):127-31. PubMed ID: 12672789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
    Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
    Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
    J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
    Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
    Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.